Skip to main content
Top

Open Access 08-04-2024 | Post-COVID Syndrome | Research

Definition of the Post-COVID syndrome using a symptom-based Post-COVID score in a prospective, multi-center, cross-sectoral cohort of the German National Pandemic Cohort Network (NAPKON)

Authors: Katharina S. Appel, Carolin Nürnberger, Thomas Bahmer, Christian Förster, Maria Cristina Polidori, Mirjam Kohls, Tanja Kraus, Nora Hettich-Damm, Julia Petersen, Sabine Blaschke, Isabel Bröhl, Jana Butzmann, Hiwa Dashti, Jürgen Deckert, Michael Dreher, Karin Fiedler, Carsten Finke, Ramsia Geisler, Frank Hanses, Sina M. Hopff, Björn-Erik O. Jensen, Margarethe Konik, Kristin Lehnert, Susana M. Nunes de Miranda, Lazar Mitrov, Olga Miljukov, Jens-Peter Reese, Gernot Rohde, Margarete Scherer, Kristin Tausche, Johannes J. Tebbe, Jörg Janne Vehreschild, Florian Voit, Patricia Wagner, Martin Weigl, Christina Lemhöfer, the NAPKON Study Group

Published in: Infection

Login to get access

Abstract

Purpose

The objective examination of the Post-COVID syndrome (PCS) remains difficult due to heterogeneous definitions and clinical phenotypes. The aim of the study was to verify the functionality and correlates of a recently developed PCS score.

Methods

The PCS score was applied to the prospective, multi-center cross-sectoral cohort (in- and outpatients with SARS-CoV-2 infection) of the "National Pandemic Cohort Network (NAPKON, Germany)". Symptom assessment and patient-reported outcome measure questionnaires were analyzed at 3 and 12 months (3/12MFU) after diagnosis. Scores indicative of PCS severity were compared and correlated to demographic and clinical characteristics as well as quality of life (QoL, EQ-5D-5L).

Results

Six hundred three patients (mean 54.0 years, 60.6% male, 82.0% hospitalized) were included. Among those, 35.7% (215) had no and 64.3% (388) had mild, moderate, or severe PCS. PCS severity groups differed considering sex and pre-existing respiratory diseases. 3MFU PCS worsened with clinical severity of acute infection (p = .011), and number of comorbidities (p = .004). PCS severity was associated with poor QoL at the 3MFU and 12MFU (p < .001).

Conclusion

The PCS score correlated with patients’ QoL and demonstrated to be instructive for clinical characterization and stratification across health care settings. Further studies should critically address the high prevalence, clinical relevance, and the role of comorbidities.

Trail registration number

The cohort is registered at www.​clinicaltrials.​gov under NCT04768998.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lemhöfer C, Best N, Gutenbrunner C, Loudovici-Krug D, Teixido L, Sturm C. Gefühlte und reale Arbeitsfähigkeit von Patient*innen mit Post-COVID Symptomatik nach mildem Akutverlauf: eine Analyse des Rehabilitation Needs Questionnaire (RehabNeQ). Phys Med Rehabil Kurortmed. 2022;32:151–8. https://doi.org/10.1055/a-1674-8044.CrossRef Lemhöfer C, Best N, Gutenbrunner C, Loudovici-Krug D, Teixido L, Sturm C. Gefühlte und reale Arbeitsfähigkeit von Patient*innen mit Post-COVID Symptomatik nach mildem Akutverlauf: eine Analyse des Rehabilitation Needs Questionnaire (RehabNeQ). Phys Med Rehabil Kurortmed. 2022;32:151–8. https://​doi.​org/​10.​1055/​a-1674-8044.CrossRef
4.
go back to reference National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN) and Royal College of General Practitioners. Guideline COVID-19 rapid guideline: managing the long-term effects of COVID-19 2022. National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN) and Royal College of General Practitioners. Guideline COVID-19 rapid guideline: managing the long-term effects of COVID-19 2022.
30.
go back to reference Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: L. Erlbaum Associates; 1988. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: L. Erlbaum Associates; 1988.
Metadata
Title
Definition of the Post-COVID syndrome using a symptom-based Post-COVID score in a prospective, multi-center, cross-sectoral cohort of the German National Pandemic Cohort Network (NAPKON)
Authors
Katharina S. Appel
Carolin Nürnberger
Thomas Bahmer
Christian Förster
Maria Cristina Polidori
Mirjam Kohls
Tanja Kraus
Nora Hettich-Damm
Julia Petersen
Sabine Blaschke
Isabel Bröhl
Jana Butzmann
Hiwa Dashti
Jürgen Deckert
Michael Dreher
Karin Fiedler
Carsten Finke
Ramsia Geisler
Frank Hanses
Sina M. Hopff
Björn-Erik O. Jensen
Margarethe Konik
Kristin Lehnert
Susana M. Nunes de Miranda
Lazar Mitrov
Olga Miljukov
Jens-Peter Reese
Gernot Rohde
Margarete Scherer
Kristin Tausche
Johannes J. Tebbe
Jörg Janne Vehreschild
Florian Voit
Patricia Wagner
Martin Weigl
Christina Lemhöfer
the NAPKON Study Group
Publication date
08-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Infection
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-024-02226-9
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.